Primary Biliary Cholangitis Diagnostic Panel
This blood test panel bundles liver enzymes, cholestasis markers, autoimmune antibodies, and viral hepatitis tests to clarify PBC patterns and next steps.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a lab panel, not a single lab value. The Primary Biliary Cholangitis (PBC) Diagnostic Panel combines liver chemistry tests with autoimmune and viral hepatitis markers so you can see whether your results fit a cholestatic pattern (bile-duct–type injury), an autoimmune signal, or a different explanation for abnormal liver enzymes.
Do I need this panel?
You may consider this panel if your liver tests have been persistently abnormal—especially if alkaline phosphatase (ALP) and/or gamma-glutamyl transferase (GGT) are elevated—or if you have symptoms that can track with cholestasis such as itching, fatigue, right upper abdominal discomfort, dark urine, pale stools, or yellowing of the eyes/skin.
This panel is also useful when you are trying to make sense of “mild ALT elevation” that doesn’t match your symptoms, or when you want to separate lab noise from a consistent pattern over time. Because PBC is an autoimmune condition that targets small bile ducts, antibody testing (especially antimitochondrial antibody, AMA) is often interpreted alongside cholestasis markers rather than in isolation.
You might also benefit from this panel if you have overlapping digestive or inflammatory conditions (for example inflammatory bowel disease) and you want to rule out common look-alikes such as viral hepatitis, medication-related liver injury, fatty liver disease, or autoimmune hepatitis overlap.
This panel supports clinician-directed care by organizing multiple related results into one view; it is not meant to diagnose you on its own or replace imaging, clinical evaluation, or specialist follow-up when indicated.
This panel includes standard blood-based immunoassays and chemistry tests; reference ranges and flags can vary by lab, so patterns and trends matter as much as any single number.
Lab testing
Order the Primary Biliary Cholangitis Diagnostic Panel
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order a multi-marker lab panel when you want a clearer picture of what your liver tests are doing over time. Instead of chasing one-off labs, this panel bundles the core markers that clinicians commonly use to evaluate a cholestatic pattern and screen for autoimmune and viral causes.
After you get results, you can use PocketMD to walk through what changed, which results belong together (for example ALP/GGT with bilirubin), and which follow-ups are worth prioritizing based on your symptoms, medications, and history. That context is especially helpful when you are trying to interpret antibody results like AMA or ANA without overreacting to a single borderline value.
If you are monitoring a known condition or tracking response to treatment, repeating the same panel can help you compare like-to-like results and reduce confusion from partial testing.
- One order, multiple clinically related markers
- Designed for pattern recognition (cholestasis vs hepatocellular injury vs mixed)
- PocketMD support to turn a complex panel into an action plan for follow-up
Key benefits of the Primary Biliary Cholangitis Diagnostic Panel
- Clarifies whether your liver enzyme changes fit a cholestatic pattern (ALP/GGT) versus a hepatocellular pattern (ALT/AST) or a mixed picture.
- Screens for the most characteristic autoimmune signal of PBC (antimitochondrial antibody, AMA) in the same draw as liver chemistry markers.
- Helps rule out common alternative explanations for abnormal liver tests, including viral hepatitis, before you assume an autoimmune cause.
- Adds liver function context (bilirubin, albumin, prothrombin time/INR) that can matter more than enzymes alone when assessing severity.
- Supports earlier, more targeted conversations with a clinician about next steps such as imaging, additional antibody subtypes, or referral.
- Improves monitoring by keeping key markers together, making trends easier to interpret than scattered single tests ordered at different times.
- Reduces “alphabet soup” confusion by grouping related results into a coherent story you can review with PocketMD.
What is the Primary Biliary Cholangitis Diagnostic Panel?
The Primary Biliary Cholangitis (PBC) Diagnostic Panel is a bundled lab panel that combines liver chemistry tests, liver function markers, and immune/viral screening tests that are commonly used when PBC is on the differential diagnosis.
PBC is a chronic autoimmune cholestatic liver disease. In plain terms, the immune system targets small bile ducts inside the liver. When bile flow is impaired, certain blood tests tend to rise—most notably alkaline phosphatase (ALP) and often gamma-glutamyl transferase (GGT). Over time, ongoing cholestasis can affect bilirubin and other measures of liver function.
Because no single blood test “proves” PBC in every person, clinicians usually look for a pattern: (1) a cholestatic enzyme profile, (2) supportive autoantibodies (especially AMA, and sometimes ANA patterns), and (3) exclusion of other causes such as viral hepatitis or medication-related injury. This panel is designed to capture those categories together so your results can be interpreted as a set.
This panel does not replace imaging (such as ultrasound or MRCP) when bile duct obstruction or other structural problems are a concern, and it does not stage fibrosis on its own. It is best viewed as a targeted diagnostic and pattern-confirmation panel that can guide what to do next.
What do my panel results mean?
When results are low or not flagged
If most markers in this panel are within the lab’s reference ranges—especially ALP, GGT, and bilirubin—your results do not show a strong cholestatic signal at the time of testing. If AMA and other autoimmune markers are negative and viral hepatitis screening is negative, PBC becomes less likely, though it is not fully excluded in every scenario (for example, very early disease, fluctuating enzymes, or testing during a quiet period). In this situation, clinicians often focus on other explanations for symptoms or mild enzyme changes, and may repeat key liver enzymes over time rather than escalating immediately.
When results fit a reassuring pattern for your situation
An “optimal” panel pattern depends on why you tested. If you were screening because of a mild, isolated enzyme elevation, an optimal pattern is typically: normal bilirubin and liver function markers, no viral hepatitis evidence, and no strong autoimmune antibody signal—plus a stable trend on repeat testing. If you are monitoring known PBC, an optimal pattern often means cholestasis markers (ALP and GGT) are improved or stable on therapy, bilirubin remains normal, and synthetic function (albumin and INR/prothrombin time) stays in a healthy range. Your clinician may still use symptoms, imaging, and trend data to decide whether any adjustments are needed.
When results are high or show a concerning pattern
A pattern that raises suspicion for PBC commonly includes persistently elevated ALP (often with elevated GGT) with relatively smaller increases in ALT/AST, along with a positive AMA. If bilirubin is elevated or albumin/INR are abnormal, that can suggest more significant cholestasis or impaired liver function and usually warrants timely medical follow-up. If viral hepatitis markers are positive, the interpretation changes—viral infection can drive enzyme elevations and must be addressed directly. If ALT/AST are markedly higher than ALP, or if autoimmune markers suggest overlap (for example autoimmune hepatitis features), clinicians may broaden evaluation and consider additional antibody testing, immunoglobulins, imaging, and sometimes biopsy depending on the full picture.
Factors that influence panel results
Many non-PBC factors can shift this panel. Medications and supplements (including some antibiotics, antifungals, anti-seizure medications, anabolic agents, and certain herbal products) can raise liver enzymes and sometimes mimic cholestasis. Alcohol use, fatty liver disease/metabolic dysfunction, recent strenuous exercise, and acute illness can affect AST/ALT. Pregnancy and hormonal factors can influence ALP (and ALP can also rise from bone sources), so pairing ALP with GGT helps clarify whether the signal is liver-related. Autoimmune antibodies can be present at low levels in some people without active liver disease, so a single borderline antibody result is usually interpreted alongside enzyme patterns and repeat testing. Finally, timing matters: a one-time snapshot may miss fluctuations, which is why trends and consistent testing conditions are valuable.
What’s included in this panel
- Actin (Smooth Muscle) Antibody (Igg)
- Ana Screen, Ifa
- Liver Kidney Microsomal (Lkm-1) Ab (Igg)
- Mitochondrial Ab Screen
- Sjogren'S Antibody (Ss-A)
- Sjogren'S Antibody (Ss-B)
- Thyroid Peroxidase Antibodies
Frequently Asked Questions
Can this panel diagnose primary biliary cholangitis (PBC) by itself?
This panel can strongly support or reduce suspicion for PBC, but diagnosis is usually based on a combination of a cholestatic lab pattern (often elevated ALP), supportive antibodies (often AMA), and clinical evaluation. Imaging and sometimes additional tests are used to rule out bile duct obstruction or other liver diseases.
Do I need to fast before this panel?
Fasting is not usually required for the core liver enzymes and antibody tests in this panel. If you are combining this panel with other tests (such as lipids or glucose/insulin), fasting instructions may change. Follow the instructions provided with your order.
What pattern is most suggestive of PBC on a lab panel?
A common PBC-supportive pattern is persistently elevated ALP (often with elevated GGT), relatively smaller ALT/AST increases, and a positive antimitochondrial antibody (AMA), especially AMA-M2. Normal or mildly changed bilirubin can occur early; rising bilirubin or abnormal albumin/INR can indicate more advanced impact and should be discussed promptly with a clinician.
What if my AMA is positive but my liver enzymes are normal?
A positive AMA can occur before clear enzyme changes, but it can also be seen at low levels without active disease. In practice, clinicians usually interpret AMA alongside ALP/GGT trends, symptoms, and sometimes repeat testing. If AMA is positive, it is reasonable to discuss follow-up timing and whether additional markers or imaging are appropriate.
How is PBC different from autoimmune hepatitis or PSC?
PBC typically shows a cholestatic pattern (ALP/GGT) and is often AMA-positive. Autoimmune hepatitis more often shows a hepatocellular pattern (higher ALT/AST) and may involve different antibodies and elevated IgG rather than IgM. Primary sclerosing cholangitis (PSC) is often associated with inflammatory bowel disease and is evaluated heavily with imaging of the bile ducts; labs can overlap, so imaging and clinical context are key.
Is it better to order a panel instead of individual tests?
When you are trying to explain abnormal liver enzymes or evaluate for PBC, a panel is often more useful than single tests because interpretation depends on patterns across enzymes, bilirubin, liver function markers, and antibody/viral screening. Ordering them together also reduces the chance of missing a key piece of the picture.
How often should I repeat this panel if I am monitoring a known issue?
Repeat timing depends on your diagnosis, symptoms, and treatment plan. Some people recheck key markers every few months during medication changes and less often when stable. The most helpful approach is repeating the same core markers consistently so trends are clear; your clinician can tailor the interval to your situation.